Cholestatic Pruritus Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Cholestatic Pruritus Market?

The cholestatic pruritus market size has experienced robust growth in recent years. It is forecast to expand from $20.22 billion in 2025 to $21.3 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This growth during the historical period is attributable to several factors, including the increasing prevalence of chronic liver diseases, the limited efficacy of traditional antihistamines, the advancement of hepatology specialty care, a rise in the diagnosis of cholestatic disorders, and the expansion of supportive care treatments.

The cholestatic pruritus market is projected to experience robust expansion in the upcoming years. It is anticipated to grow to $25.99 billion by 2030, at a compound annual growth rate (CAGR) of 5.1%. This growth during the forecast period can be attributed to the increasing approval of novel therapeutics, a rising emphasis on improving quality of life, the expansion of targeted liver disease drugs, growing investment in rare disease research, and the increasing adoption of personalized treatment plans. Major trends expected in this period include the increasing development of targeted anti-pruritic therapies, a heightened focus on symptom-specific treatment approaches, the growing utilization of oral bile acid modulators, the expansion of research in liver disease management, and enhanced patient-centered care strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp

Which Strategic Drivers Are Supporting The Cholestatic Pruritus Market Development?

The future expansion of the cholestatic pruritus market is anticipated to be driven by the rising occurrence of liver diseases. These diseases encompass a wide spectrum of ailments impacting liver function, such as infections, autoimmune conditions, inherited disorders, and toxin-induced damage, which can result in inflammation, fibrosis, or liver failure. The escalating incidence of liver conditions is attributed to factors like rising obesity rates, diabetes, alcohol consumption, viral hepatitis infections, and exposure to environmental toxins. Cholestatic pruritus plays a crucial role in identifying and managing liver ailments, acting as a significant symptom that points to compromised bile flow, thereby frequently triggering additional diagnostic procedures and therapeutic interventions for underlying liver problems. For example, in 2023, data from the Office for Health Improvement and Disparities (OHID), a UK government body, revealed that England recorded 85,665 hospital admissions for liver disease within the fiscal year concluding in 2023. Consequently, the expanding occurrence of liver diseases will stimulate the growth of the cholestatic pruritus market.

What Segment Types Are Included In The Cholestatic Pruritus Market Analysis?

The cholestatic pruritus market covered in this report is segmented –

1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis Of Pregnancy (ICP), Other Disease Types

2) By Treatment Type: Medications, Phototherapy, Other Treatment Types

3) By Route Of Administration: Oral, Topical, Injectable

4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare

Subsegments:

1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure

2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures

3) By Intrahepatic Cholestasis Of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk

4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders

What Trends Are Shaping The Cholestatic Pruritus Market Structure?

Major companies operating in the cholestatic pruritus market are prioritizing the creation of novel solutions, specifically oral solutions, aimed at more effective symptom management, improved patient adherence, and providing precise relief by tackling the underlying causes of bile salt accumulation and inflammation. An oral solution for the treatment of cholestatic pruritus is a liquid drug formulation designed to reduce bile acid accumulation and mitigate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution for addressing cholestatic pruritus in patients aged five and older diagnosed with progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered ileal bile acid transporter inhibitor possesses a breakthrough therapy designation for PFIC type 2. LIVMARLI is anticipated to make a substantial difference for patients suffering from cholestatic pruritus linked to PFIC, offering a much-needed therapeutic option for those with the rarest subtypes.

Which Companies Are Engaged In The Cholestatic Pruritus Market Environment?

Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, ProQR Therapeutics NV.

Access The Complete Cholestatic Pruritus Market Report:

https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report

Which Geographic Region Represents The Largest Cholestatic Pruritus Market Share?

North America was the largest region in the cholestatic pruritus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cholestatic Pruritus Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21140&type=smp

Browse Through More Reports Similar to the Global Cholestatic Pruritus Market 2026, By The Business Research Company

Gastrointestinal Stromal Tumor Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Liver Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Invasive Ductal Carcinoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795